2014
DOI: 10.1097/jcp.0000000000000099
|View full text |Cite
|
Sign up to set email alerts
|

Treatment Outcomes of Depression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
24
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
5
2
2

Relationship

4
5

Authors

Journals

citations
Cited by 43 publications
(24 citation statements)
references
References 14 publications
0
24
0
Order By: Relevance
“…The sample comprised 240 MDD participants from the Mayo Clinic NIH-Pharmacogenomics Research Network - Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) (Mrazek et al, 2014). Participant selection, symptomatic evaluation, and blood sample collection for the PGRN-AMPS clinical trial have been described in our previous work (Gupta et al, 2016; Ji et al, 2014; Mrazek et al, 2014; Schiepers, Wichers, & Maes, 2005). MDD symptoms were assessed using the HRSD 17 at baseline and after eight weeks of treatment with citalopram or escitalopram.…”
Section: Methodsmentioning
confidence: 99%
“…The sample comprised 240 MDD participants from the Mayo Clinic NIH-Pharmacogenomics Research Network - Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) (Mrazek et al, 2014). Participant selection, symptomatic evaluation, and blood sample collection for the PGRN-AMPS clinical trial have been described in our previous work (Gupta et al, 2016; Ji et al, 2014; Mrazek et al, 2014; Schiepers, Wichers, & Maes, 2005). MDD symptoms were assessed using the HRSD 17 at baseline and after eight weeks of treatment with citalopram or escitalopram.…”
Section: Methodsmentioning
confidence: 99%
“…11, 36, 37 Plasma metabolite concentrations were assayed using samples from 306 randomly selected MDD patients at baseline and after four and eight weeks of SSRI therapy using a high-performance liquid chromatography electrochemical coulometric array (LCECA) metabolomics platform. 31, 39 See Supplementary Text for details.…”
Section: Methodsmentioning
confidence: 99%
“…SNPs with the smallest P -values in each of the top 10 association regions in the two primary analyses (that is, top SNP in each region) were tested for association with equivalent outcomes in two independent samples: the PGRN-AMPS 15 and STAR*D. 14 GWA analyses utilizing these two samples are published, 5 , 7 and both data sets are available through controlled access via the database for Genotypes and Phenotypes (dbGaP; http://www.ncbi.nlm.nih.gov/gap ).…”
Section: Methodsmentioning
confidence: 99%
“…This is the first report of findings from a GWAS of SSRI treatment response based on the ISPC sample. Data from two prior GWAS of SSRI response, the Mayo Clinic Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) 7 , 15 and the STAR*D study, 14 were used for replication analysis, and a meta-analysis of the three studies was performed.…”
Section: Introductionmentioning
confidence: 99%